Evidence map›Paper›PMID 37333087›Full record

ArticleResearch square2023

Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): Study protocol for an adaptive randomized controlled trial.

Jesse E Ross, Rubeshan Perumal, Allison Wolf, Mbali Zulu, Kevin Guzman, Boitumelo Seepamore, Karl Reis, Hlengiwe Nyilana, Senzo Hlathi, Radhamoney Narasimmulu and 7 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 4 countries.

Jesse E RossColumbia University Department of Medicine.ORCID 0009-0008-3405-0897
Rubeshan PerumalCAPRISA: Centre for the Aids Programme of Research in South Africa.
Allison WolfCUIMC: Columbia University Irving Medical Center.
Mbali ZuluCAPRISA: Centre for the Aids Programme of Research in South Africa.
Kevin GuzmanCUIMC: Columbia University Irving Medical Center.
Boitumelo SeepamoreCAPRISA: Centre for the Aids Programme of Research in South Africa.
Karl ReisColumbia University Vagelos College of Physicians and Surgeons.
Hlengiwe NyilanaCAPRISA: Centre for the Aids Programme of Research in South Africa.
Senzo HlathiCAPRISA: Centre for the Aids Programme of Research in South Africa.
Radhamoney NarasimmuluCAPRISA: Centre for the Aids Programme of Research in South Africa.
Ying Keun K CheungCUIMC: Columbia University Irving Medical Center.
K Rivet AmicoUniversity of Michigan School of Public Health.
Gerald FriedlandYale School of Medicine: Yale University School of Medicine.
Amrita DaftaryYork University Dahdaleh Institute for Global Health Research.
Jennifer ZelnickTouro College Graduate School of Social Work.
Kogieleum NaidooCAPRISA: Centre for the Aids Programme of Research in South Africa.
Max R O'DonnellCUIMC: Columbia University Irving Medical Center.
Centre for the AIDS Programme of Research in South Africa · ZAColumbia University Irving Medical Center · USColumbia College · CAColumbia University · USTouro College · USUniversity of Michigan · USYale University · US

Funding

Novel Reporter Phages to Detect Complex TB Drug Resistance and PersistenceR01AI114900 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Michelle H Larsen, Max O'Donnell · 2015 to 2026
$7.2M
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South AfricaR01AI167795 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Max O'Donnell · 2022 to 2026
$2.9M
A Microfluidic Diffusion ImmunoassayR01EB002023 · NIBIB · UNIVERSITY OF WASHINGTON · PI YAGER, PAUL · 2003 to 2004
$513k
NIAID NIH HHS R01 AI114900NIAID NIH HHS R01 AI167795NIBIB NIH HHS R01 EB002023
6 · The paper itself

Abstract

Background: Highly effective, short course, bedaquiline-containing treatment regimens for multidrug-resistant tuberculosis (MDR-TB) and integrase strand transfer inhibitor (INSTI)-containing fixed dose combination antiretroviral therapy (ART) have radically transformed treatment for MDR-TB and HIV. However, without advances in adherence support, we may not realize the full potential of these therapeutics. The primary objective of this study is to compare the effect of adherence support interventions on clinical and biological endpoints using an adaptive randomized platform. Methods: This is a prospective, adaptive, randomized controlled trial comparing the effectiveness of four adherence support strategies on a composite clinical outcome in adults with MDR-TB and HIV initiating bedaquiline-containing MDR-TB treatment regimens and receiving ART in KwaZulu-Natal, South Africa. Trial arms include 1) enhanced standard of care; 2) psychosocial support; 3) mHealth using cellular- enabled electronic dose monitoring; 4) combined mHealth and psychosocial support. The level of support will be titrated using a differentiated service delivery (DSD)-informed assessment of treatment support needs. The composite primary outcome will be include survival, negative TB culture, retention in care and undetectable HIV viral load at month 12. Secondary outcomes will include individual components of the primary outcome and quantitative evaluation of adherence on TB and HIV treatment outcomes. Discussion: This trial will evaluate the contribution of different modes of adherence support on MDR-TB and HIV outcomes with WHO recommended all-oral MDR-TB regimens and ART in a high-burden operational setting. We will also assess the utility of a DSD framework to pragmatically adjust levels of MDR-TB and HIV treatment support.

Indexed as

Adherence supportAntiretroviralsBedaquilineHIV/AIDSMDR-TBmHealthSouth AfricaTuberculosis

Identifiers

PMID37333087
PMCPMC10274958
OpenAlexW4380081914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.